Clinical trials: Mucinous Tumor
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma
- Trial name
- NCT00888173
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 35 sites in United States
- Volunteers
- 45 people
- Sponsor
- Gynecologic Oncology Group
Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
The purpose of this study is to find the highest dose of a drug, samuraciclib, that can be given with standard of care chemotherapy (gemcitabine and nab-paclitaxel) without causing very severe side effects.
- Conditions
- Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic, Pancreatic Adenocarcinoma Metastatic, Adenosquamous Carcinoma of the Pancreas
- Trial name
- SONIC (NCT07665684)
- Testing
- Samuraciclib + Gemcitabine & Nab-Paclitaxel
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- University Health Network, Toronto
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase II trial studies how well v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor MK2206 works in treating patients with previously treated colon or rectal cancer that has spread from the primary site to other…
- Conditions
- Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
- Trial name
- NCT01802320
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer
This randomized phase II trial studies how well radiation therapy and capecitabine with or without curcumin before surgery works in treating patients with rectal cancer.
- Conditions
- Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7
- Trial name
- NCT00745134
- Testing
- Capecitabine, Curcumin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer
Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer
This phase I trial studies the side effects and best dose of fluorouracil when given together with radiation therapy followed by combination chemotherapy before and after surgery in treating patients with rectal cancer that has…
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma
- Trial name
- NCT02270606
- Testing
- intensity-modulated radiation therapy, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Commonwealth University
Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU
Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)
Cystic lesions of the pancreas are frequent with a risk of degeneration into adenocarcinoma with pejorative prognosis. IPMNs require characterization to clarify their potential for degeneration.
- Trial name
- IPMN (NCT04901364)
- Testing
- Sensitivity and specificity of risk factors for degeneration of IPMNs
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Central Hospital, Nancy, France
Breast Cancer Female NOS, Tubular Breast Cancer Stage II
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models.
- Conditions
- Breast Cancer Female NOS, Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Invasive Ductal Breast Cancer
- Trial name
- GeparX (NCT02682693)
- Testing
- Denosumab, nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 780 people
- Sponsor
- GBG Forschungs GmbH
Colorectal Cancer
Second Look Laparoscopy in Colorectal Cancer
The purpose of this study is to evaluate whether a second-look laparoscopy, followed by peritonectomy, hyperthermic intraperitoneal chemotherapy (HIPEC) or systemic chemotherapy in case of peritoneal carcinosis, improves the…
- Trial name
- HIPEC (NCT01628211)
- Testing
- Laparoscopy, peritonectomy, Folinic Acid
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute, Naples
Pancreatic Cyst, IPMN
Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions
The purpose of this study is to determine clinical impact of EUS-guided microbiopsy procedure and supplementary molecular analyses compared to standard diagnostic workup of pancreatic cysts.
- Conditions
- Pancreatic Cyst, IPMN, Mucinous Cyst, Pancreatic Adenocarcinoma
- Trial name
- NCT03578445
- Testing
- EUS-guided microbiopsy, Next Generation Sequencing
- Where
- Denmark
- Volunteers
- 101 people
- Sponsor
- Herlev Hospital
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Pancreas Cancer
Pancreas Cancer Surveillance Using an Abbreviated MRI
This study aims to establish a prospective cohort of developing pancreas cancer and surveillance MRI protocol. With the focused surveillance protocol, we perform surveillance for pancreas cancer for five years to estimate the…
- Trial name
- NCT04592393
- Testing
- Abbreviated PB MRI, Gene mutation test, Conventional follow-up
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003644
- Testing
- carboplatin, paclitaxel
- Where
- 151 sites in United States, Japan
- Volunteers
- 571 people
- Sponsor
- Gynecologic Oncology Group
Pancreatic Diseases
PAncreatic Disease Cohort of TOuLouse
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies.
- Trial name
- PACTOL (NCT05824403)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Toulouse
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00100841
- Testing
- cetuximab, bevacizumab, oxaliplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01167725
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Where
- 2 sites in United States
- Volunteers
- 340 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the combination of pembrolizumab, bevacizumab, and low dose oral cyclophosphamide in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT02853318
- Testing
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01814501
- Testing
- panitumumab, irinotecan hydrochloride, fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- John Hays
Pancreatic Cyst
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery.
- Trial name
- NCT06305728
- Testing
- 89Zr-DFO-HuMab-5B1 immunoPET, HP MRI, Blood assay
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cystic Lesion, Mucinous Cystadenoma of Pancreas
Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data
The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic…
- Conditions
- Pancreatic Cystic Lesion, Mucinous Cystadenoma of Pancreas, Intraductal Papillary Mucinous Neoplasm of Pancreas, Pseudocyst Pancreas
- Trial name
- NCT07463872
- Testing
- Cyst-AI model
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Huazhong University of Science and Technology
Neoplasms, Cystic, Mucinous, and Serous
Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
Cystic tumors of the pancreas are fluid-filled growths. They are often treated by surgical removal. A safe and effective non-surgical treatment is desirable.
- Trial name
- NCT02158039
- Testing
- Ethanol, Lidocaine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic